Wendy Cheng

Boston
Education
Ph.D. and M.P.H., epidemiology, Columbia University; B.S., psychobiology, University of California, Los Angeles
Summary of Experience
Dr. Cheng specializes in applying epidemiologic methods to assess the causal relationship of therapeutic agents with health and safety outcomes in observational studies. Her experience includes new drug application (NDA) contingency studies and post-authorization safety studies (PASS) for regulatory bodies; natural history studies; and real-world evidence development across multiple therapeutic areas. Dr. Cheng has particular expertise in applying advanced methodologies to address complex health care research challenges. She has used machine learning and other predictive modeling techniques, including latent class analysis to identify cost clusters in disease patient population, group-based trajectory analysis to identify disease prognosis patterns, and rule-based approaches to diagnostic algorithms. Dr. Cheng has collected and utilized data from administrative insurance claims, large patient and physician surveys, clinical trials, electronic medical records, longitudinal observational studies, and site-based and panel-based medical chart reviews. She has conducted studies in more than 10 countries and published her research in numerous medical journals. Prior to joining Analysis Group, Dr. Cheng served as a research scientist at Columbia University and worked as a biostatistician in the Clinical Trials Network of the National Institute on Drug Abuse.
Selected Publishing
-
Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study
Annals of Dermatology, 2022
2022Choi GS, Sim WY, Kang H, Huh CH, Lee YW, Shantakumar S, Ho YF, Oh EJ, Duh MS, Cheng WY, Bobbili P, Thompson-Leduc P, Ong G
-
Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes
Journal of Hematology, 2021
2021Cheng WY, Satija A, Cheung HC, Hill K, Wert T, Laliberté F, Lefebvre P
-
Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study
Journal of Endocrinological Investigation, 2020
2020Colao A, Grasso LFS , Di Cera M, Thompson-Leduc P, Cheng WY, Cheung HC, Duh MS, Neary MP, Pedroncelli AM, Maamari R, Pivonello R
-
Determinants of Meningococcal ACWY vaccination in adolescents in the US: completion and compliance with the CDC recommendations
Human Vaccines & Immunotherapeutics, 2020
2020 -
Development of a classifier to identify patients with probable Lennox-Gastaut syndrome in health insurance claims databases via random forest methodology
Current Medical Research and Opinion, 2019
2019Vekeman F, Piña-Garza JE, Cheng WY, Tuttle E, Giguère-Duval P, Oganisian A, Damron J, Duh MS, Shen V, Saurer TB, Montouris GD, Isojarvi J
-
Real-world treatment patterns among patients with advanced gastric cancer in Russia: a chart review study
Journal of Drug Assessment, 2019
2019Tjulandin SA, Tryakin AA, Besova NS, Sholokhova E, Ivanova JI, Cheng WY, Schmerold LM, Thompson-Leduc P, Novick D
-
The role of provider characteristics on the hepatitis A and B vaccination status of adults in the United States during 2007-2015
Preventive Medicine Reports, 2019
2019Ghaswalla PK, Patterson BJ, Cheng WY, Duchesneau E, Macheca M, Duh MS, Trofa AF
-
Comorbidities and Survival in Patients With Lipodystrophy: An International Chart Review Study
The Journal of Clinical Endocrinology and Metabolism, 2019
2019Akinci B, Oral EA, Neidert A, Rus D, Cheng WY, Thompson-Leduc P, Cheung HC, Bradt P, de Freitas MCF, Montenegro RM, Fernandes VO, Cochran E, Brown RJ
-
Epidemiologic and clinical characteristics of nontransfusion-dependent thalassemia in the United States
Pediatric Blood & Cancer. Apr 10 2018:e27067
2018Vichinsky E, Cohen A, Thompson AA, Giardina PJ, Lal A, Paley C, Cheng WY, McCormick N, Sasane M, Qiu Y, Kwiatkowski JL
-
Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets
Current Medical Research and Opinion. Apr 27 2018:1-14
2018Cheng WY, Said Q, Hao Y, Xiao Y, Vekeman F, Bobbili P, Duh MS, Nandal S, Blinder M
-
Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia
Clinical Lymphoma, Myeloma & Leukemia. Apr 2018;18(4):257-265
2018Jabbour E, DerSarkissian M, Duh MS, McCormick N, Cheng WY, McGarry LJ, Souroutzidis A, Huang H, O'Brien S, Ravandi F, Kantarjian HM
-
Hepatitis A, B, and A/B vaccination series completion among US adults: A claims-based analysis
Human Vaccines and Immunotherapeutics, July 12, 2018
2018Ghaswalla P, Patterson B, Cheng W, Duchesneau E, Macheca M, Duh MS
-
Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication
BMC Infectious Diseases, 2018 Aug 29;18(1):438
2018Vekeman F, Weiss L, Aram J, Ionescu-Ittu R, Moosavi S, Xiao Y, Cheng WY, Bhak RH, Tawadrous M, Capparella MR, Montravers P, Duh MS
-
Predictors and clinical outcomes of treatment intensification in patients with type 2 diabetes uncontrolled on basal insulin in a real-world setting
Endocrine Practice. 2018 Sep;24(9):805-814.
2018Kallenbach L, Shui AM, Cheng WY, Fan T, Hu W, Zichlin ML, Duh MS, Ye F, Levin PA
-
Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting
Medical Oncology. Aug 10 2017;34(9):160
2017Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS
-
Real-world Characteristics and Outcomes of Patients with Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy versus Androgen Receptor-targeted Therapy after Failure of First-line And
Clinical Genitourinary Cancer. 2017 Jun 19. pii: S1558-7673(17)30170-2
2017Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS
-
Assessment of treatment patterns and healthcare costs associated with probable Lennox-Gastaut syndrome
Epilepsy & Behavior. Aug 2017;73:46-50
2017Piña-Garza JE, Montouris GD, Vekeman F, Cheng WY, Tuttle E, Giguere-Duval P, Duh MS, Shen V, Saurer TB, Isojarvi J
-
Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia
Journal of Medical Economics, 2016 03; 19(3): 292-303. e-pub ahead of print 2015/12/01
2016Vekeman F, Sasane M, Cheng WY, Ramanakumar AV, Fortier J, Qiu Y, Duh MS, Paley C, Adams-Graves P.
-
Positive subjective measures in abuse liability studies and real-world nonmedical use: Potential impact of abuse-deterrent opioids on rates of nonmedical use and associated healthcare costs
J Opioid Manag. 2015 May-Jun;11(3):199-210
2015White AG, LeCates J, Birnbaum HG, Cheng W, Roland CL, Mardekian J
-
Clinical burden of asynchrony in patients with asthma when using metered-dose inhalers for control
Allergy and Asthma Proceedings, Jan 01 2019; 40(1): p. 21-31.
Ferro TJ, Sundaresan AS, Pitcavage JM, Ivanova JI, Schmerold L, Ariely R, Parikh R, Cheng WY
-
Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting
Urologic Oncology. 2018 Nov;36(11):500.e1-500.e9
Oh WK, Cheng WY, Miao R, Vekeman F, Gauthier-Loiselle M, Duh MS, Drea E, Szatrowski TP
News
-
March 29, 2022
-
December 10, 2021
-
October 15, 2021
-
June 4, 2021